Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables

PartnershipPharmaShellPositive

AI Analysis

Summary

Nanexa and Novo entered into a EUR 1.165 billion global license and collaboration agreement granting Novo exclusive rights to Nanexa's PharmaShell ALD drug delivery technology platform for therapeutic peptide drugs in obesity, type 2 diabetes, and cardiometabolic diseases.

Outcome Details

Global exclusive license agreement for PharmaShell ALD drug delivery technology platform for therapeutic peptide drugs

Importance:7/10

Sentiment:

0.70

licensingcollaborationdrug deliverytherapeutic peptidesobesitydiabetes

Related Companies

$GBCMD $DMIIR

Read the original article

Published by PR Newswire Biotech on September 25, 2026 12:00 PM

Read Original